Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations
Medical Journal of Australia · 2025
DOI: 10.5694/mja2.70061 ↗Kurz gefasst
Leitlinie in der Zeitschrift Medical Journal of Australia, 2025. Verfasst von Jacob George und 30 weiteren Autor:innen. Beteiligte Einrichtung: Storr Liver Centre, Westmead Institute for Medical Research, Sydney, NSW. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Early Detection of Cancer, Liver Neoplasms. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Health and Aged Care, Australian Government.
Abstract (Originalsprache)
Introduction Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, the sixth most common cause of cancer death in Australia. With shifting aetiologies and a growing at‐risk population, consistent routine surveillance recommendations are key to early detection of HCC and improved survival. We developed new evidence‐based HCC surveillance guidelines for people at high risk in Australia due to liver disease and/or other risk factors. These guidelines were developed by a working group of experts in liver cancer control and included evidence reviews, synthesis and adaptation of existing guidelines for the Australian context, and predictive modelling. Main recommendations This article summarises the recommendations and practice points for key population subgroups who were identified as potentially benefitting from routine HCC surveillance in the form of six‐monthly ultrasound scans, with or without α‐fetoprotein testing. People with liver cirrhosis and a non‐HCC‐related life expectancy of greater than six months are recommended to receive routine HCC surveillance. People with chronic hepatitis B virus infection who do not have liver cirrhosis are recommended to receive routine HCC surveillance if they have a family history of HCC, are Aboriginal or Torres Strait Islander peoples, or have an Asian, Pacific, or sub‐Saharan African background, with varying start ages recommended for each group. People with stage 3 non‐cirrhotic liver fibrosis (F3) may be recommended to receive routine HCC surveillance based on individual risk assessment, or otherwise monitored for progression to cirrhosis. The final guidelines were approved by the National Health and Medical Research Council (NHMRC) in April 2023. Changes in management as a result of the guideline The updated guidelines formalise recommendations for people with cirrhosis, identify other patient groups who are recommended for surveillance, and highlight gaps in evidence where the benefit of surveillance is unclear. These guidelines were accompanied by the Roadmap to liver cancer control , a coordinated ten‐year plan for advancing liver cancer prevention and early detection in Australia. The full guidelines can be accessed at https://cancer.org.au/clinical‐guidelines/liver‐cancer/hepatocellular‐carcinoma .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Storr Liver Centre, Westmead Institute for Medical Research, Sydney, NSW.
- University of Sydney, Sydney, NSW.
- University of Melbourne, Melbourne, VIC.
- WHO Collaborating Centre for Viral Hepatitis, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC.
- Monash University, Melbourne, VIC.
- Alfred Hospital, Melbourne, VIC.
ORCID-Profile: Jacob George, Nicole L Allard, Jane Davies, Behzad Hajarizadeh, Jennifer H MacLachlan, Catherine Brown, Victoria Freeman, Joachim Worthington
Förderung
- Department of Health and Aged Care, Australian Government
Zitieren
APA
George, J., Allard, N. L., Roberts, S. K., Adams, L. A., Davies, J., Hajarizadeh, B., MacLachlan, J. H., Mahady, S. E., Altus, R., Brown, C., Fry, D. C., Greenwood-Smith, B., Smud, N., Valery, P. C., Yussf, N., Broun, K., Campbell, D., Canfell, K., Harrison, C. C., …, & Feletto, E. (2025). Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations. Medical Journal of Australia. https://doi.org/10.5694/mja2.70061
Vancouver
George J, Allard NL, Roberts SK, Adams LA, Davies J, Hajarizadeh B, et al. Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations. Medical Journal of Australia. 2025. doi:10.5694/mja2.70061
BibTeX
@article{George2025,
author = {George, Jacob and Allard, Nicole L and Roberts, Stuart K and Adams, Leon A and Davies, Jane and Hajarizadeh, Behzad and MacLachlan, Jennifer H and Mahady, Suzanne E and Altus, Rosalie and Brown, Catherine and Fry, David C and Greenwood-Smith, Belinda and Smud, Natali and Valery, Patricia C and Yussf, Nafisa and Broun, Kate and Campbell, Denise and Canfell, Karen and Harrison, Chelsea Carle and Freeman, Victoria and Grogan, Paul and Holliday, Catherine and Hughes, Suzanne and Kelly, Anna and van Kemenade, Cathelijne and Latumahina, Claire and McAtamney, Amanda and Varlow, Megan and Worthington, Joachim and Yuill, Susan and Feletto, Eleonora},
title = {Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations},
journal = {Medical Journal of Australia},
year = {2025},
doi = {10.5694/mja2.70061}
}
EUVIMED